ArticleThe Lancet regional health. Europe2027
Sex- and age-specific trends in prescription medication use, 2005-2025: a nationwide repeated cross-sectional study.
Article in The Lancet regional health. Europe, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have documented higher medication consumption among females than males; however contemporary sex-based differences across age and therapeutic classes remain poorly characterized. Methods: We used the Danish National Prescription Registry to identify all prescriptions redeemed by Danish adults in 2005, 2015 and 2025, assessing overall medication use by sex and age. For the 30 most prescribed therapeutic classes, age-adjusted rate ratios (aRRs) with 95% confidence intervals (CI) were estimated to compare use between sexes. Polypharmacy (≥ five medications redeemed within a calendar year) was also assessed by sex and age groups. Findings: In 2025, females accounted for 52% of total medication consumption (1.98 billion Defined Daily Doses (DDDs) among females vs. 3.82 billion DDDs overall), down from 60% (1.17 billion vs. 1.96 billion DDDs) in 2005. This female excess was confined to early adulthood; from age 55 onward, male consumption exceeded that of females. While some of the higher medication use reflected a higher prevalence of certain conditions among females (e.g., thyroid disorders, osteoporosis, depression), females also exhibited a higher use of mental health medications, including antipsychotics, and, newly in 2025, ADHD medications (aRR 1.25; 95%CI 1.16-1.34). Males more frequently used cardiovascular therapies (antithrombotic agents (0.64; 0.62-0.66), insulins (0.67; 0.65-0.69)). However, the historical male cardiovascular predominance was challenged in 2025: thiazide diuretics (1.19; 1.16-1.22) and non-insulin glucose-lowering drugs were more prescribed to females (1.08; 1.01-1.16). Polypharmacy was more common among females in early adulthood but converged after age 65. Interpretation: Sex-based differences in overall medication use have narrowed over time. There is a need for continued monitoring of persistent and emerging sex differences in prescribing. Funding: No specific funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.